In October 2018 Peter Haferl, Head of International Marketing & Business and the International Medical Team paid a visit to Kuwait to support the launch of the products of AMOMED in the Middle East.

During several important meetings with local key opinion leaders and decision makers, the medical and economic value of landiolol and argipressin for physicians, patients, and payors had been highlighted. During AMOMED´s scientific presentation at the Coronary Care Unit of the Al Jahra Hospital, cardiologists were stunned by the potential of our precision medicinal products for tailored correction of atrial fibrillation and tachycardia in acute settings.

Furthermore, AMOMED was invited by the Ministry of Health to present at the monthly meeting of the Kuwait Society of Intensive Care Medicine and Anaesthesiology. The most recent publications and guidelines for the management of sepsis and septic shock were presented. The messages concerning the lifesaving potential and scientific evidence of argipressin were very well received by around 90 interested physicians at the CME (continuous medical education) accredited event.

The key opinion leader visits and meetings were excellently organized prepared by our local distribution partner, Cevomed.  Mentioned activities will support AMOMED in helping more physicians and patients to manage acute and life-threatening situations faster and better.